BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim SS, Nakakura EK, Wang ZJ, Kim GE, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Ko AH. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy? J Surg Oncol. 2016;114:587-596. [PMID: 27444658 DOI: 10.1002/jso.24375] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Swords DS, Francis SR, Lloyd S, Garrido-laguna I, Mulvihill SJ, Gruhl JD, Christensen MC, Stoddard GJ, Firpo MA, Scaife CL. Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative Chemotherapy. J Gastrointest Surg 2019;23:1401-13. [DOI: 10.1007/s11605-018-3953-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
2 Janssen QP, van Dam JL, Kivits IG, Besselink MG, van Eijck CHJ, Homs MYV, Nuyttens JJME, Qi H, van Santvoort HJ, Wei AC, de Wilde RF, Wilmink JW, van Tienhoven G, Groot Koerkamp B. Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Ann Surg Oncol 2021. [PMID: 34142290 DOI: 10.1245/s10434-021-10276-8] [Reference Citation Analysis]
3 Zhang Y, Huang ZX, Song B. Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma. World J Gastroenterol 2021; 27(22): 3037-3049 [PMID: 34168406 DOI: 10.3748/wjg.v27.i22.3037] [Reference Citation Analysis]
4 Cloyd JM, Wang H, Egger ME, Tzeng CD, Prakash LR, Maitra A, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Overman MJ, Koay EJ, Das P, Herman JM, Kim MP, Vauthey JN, Aloia TA, Fleming JB, Lee JE, Katz MHG. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017;152:1048-1056. [PMID: 28700784 DOI: 10.1001/jamasurg.2017.2227] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 11.0] [Reference Citation Analysis]
5 Thanikachalam K, Damarla V, Seixas T, Dobrosotskaya I, Wollner I, Kwon D, Winters K, Raoufi M, Li J, Siddiqui F, Khan G. Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer. Am J Clin Oncol 2020;43:435-41. [PMID: 32251119 DOI: 10.1097/COC.0000000000000688] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Glinka J, Diaz F, Alva A, Mazza O, Sanchez Claria R, Ardiles V, de Santibañes E, Pekolj J, de Santibañes M. Use of radiotherapy in patients with palliative double bypass for locally advanced pancreatic adenocarcinoma. Radiat Oncol J 2018;36:210-7. [PMID: 30309212 DOI: 10.3857/roj.2018.00206] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Nagakawa Y, Sahara Y, Hosokawa Y, Murakami Y, Yamaue H, Satoi S, Unno M, Isaji S, Endo I, Sho M, Fujii T, Takishita C, Hijikata Y, Suzuki S, Kawachi S, Katsumata K, Ohta T, Nagakawa T, Tsuchida A. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery. Ann Surg Oncol 2019;26:1629-36. [PMID: 30610555 DOI: 10.1245/s10434-018-07131-8] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 11.7] [Reference Citation Analysis]
8 Al-Sadairi AR, Mimmo A, Rhaiem R, Esposito F, Rached LJ, Tashkandi A, Zimmermann P, Memeo R, Sommacale D, Kianmanesh R, Piardi T. Laparoscopic hybrid pancreaticoduodenectomy: Initial single center experience. Ann Hepatobiliary Pancreat Surg 2021;25:102-11. [PMID: 33649262 DOI: 10.14701/ahbps.2021.25.1.102] [Reference Citation Analysis]
9 Cloyd JM, Chen H, Wang X, Tzeng CD, Kim MP, Aloia TA, Vauthey J, Lee JE, Katz MH. Chemotherapy Versus Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score Adjusted Analysis. Pancreas 2019;48:216-22. [DOI: 10.1097/mpa.0000000000001231] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 9.3] [Reference Citation Analysis]
10 Toesca DAS, Koong AJ, Poultsides GA, Visser BC, Haraldsdottir S, Koong AC, Chang DT. Management of Borderline Resectable Pancreatic Cancer. Int J Radiat Oncol Biol Phys 2018;100:1155-74. [PMID: 29722658 DOI: 10.1016/j.ijrobp.2017.12.287] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
11 Lee RC, Kanhere H, Trochsler M, Broadbridge V, Maddern G, Price TJ. Pancreatic, periampullary and biliary cancer with liver metastases: Should we consider resection in selected cases? World J Gastrointest Oncol 2018; 10(8): 211-220 [PMID: 30147847 DOI: 10.4251/wjgo.v10.i8.211] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
12 Yoshitomi H, Takano S, Furukawa K, Takayashiki T, Kuboki S, Ohtsuka M. Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues. Surg Today 2019;49:894-906. [PMID: 30949842 DOI: 10.1007/s00595-019-01804-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
13 Lindemann J, du Toit L, Kotze U, Bernon M, Krige J, Jonas E. Survival equivalence in patients treated for borderline resectable and unresectable locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis. HPB (Oxford) 2021;23:173-86. [PMID: 33268268 DOI: 10.1016/j.hpb.2020.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Saito K, Isayama H, Sakamoto Y, Nakai Y, Ishigaki K, Tanaka M, Watadani T, Arita J, Takahara N, Mizuno S, Kogure H, Ijichi H, Tateishi K, Tada M, Hasegawa K, Fukayama M, Kokudo N, Koike K. A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer. Med Oncol. 2018;35:100. [PMID: 29846849 DOI: 10.1007/s12032-018-1158-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
15 Hashimoto D, Chikamoto A, Masuda T, Nakagawa S, Imai K, Yamashita YI, Reber HA, Baba H. Pancreatic Cancer Arising From the Remnant Pancreas: Is It a Local Recurrence or New Primary Lesion? Pancreas 2017;46:1083-90. [PMID: 28902776 DOI: 10.1097/MPA.0000000000000897] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
16 Rosati LM, Kumar R, Herman JM. Integration of Stereotactic Body Radiation Therapy into the Multidisciplinary Management of Pancreatic Cancer. Semin Radiat Oncol 2017;27:256-67. [PMID: 28577833 DOI: 10.1016/j.semradonc.2017.02.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
17 Polish A, Joseph NE, Marsh RW. Pathologic Response to Primary Systemic Therapy With FOLFIRINOX in Patients With Resectable Pancreatic Cancer. Am J Clin Oncol 2019;42:761-6. [PMID: 31569128 DOI: 10.1097/COC.0000000000000601] [Reference Citation Analysis]
18 Nakagawa K, Akahori T, Nishiwada S, Nagai M, Nakamura K, Tanaka T, Tamamoto T, Ohbayashi C, Hasegawa M, Kichikawa K, Ikeda N, Sho M. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma. Langenbecks Arch Surg 2018;403:693-700. [PMID: 30218193 DOI: 10.1007/s00423-018-1709-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
19 Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali MA, Besselink MG, Boone BA, Chau I, Clarke S, Dillhoff M, El-Rayes BF, Frakes JM, Grose D, Hosein PJ, Jamieson NB, Javed AA, Khan K, Kim KP, Kim SC, Kim SS, Ko AH, Lacy J, Margonis GA, McCarter MD, McKay CJ, Mellon EA, Moorcraft SY, Okada KI, Paniccia A, Parikh PJ, Peters NA, Rabl H, Samra J, Tinchon C, van Tienhoven G, van Veldhuisen E, Wang-Gillam A, Weiss MJ, Wilmink JW, Yamaue H, Homs MYV, van Eijck CHJ, Katz MHG, Groot Koerkamp B. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. J Natl Cancer Inst 2019;111:782-94. [PMID: 31086963 DOI: 10.1093/jnci/djz073] [Cited by in Crossref: 77] [Cited by in F6Publishing: 72] [Article Influence: 38.5] [Reference Citation Analysis]
20 Choi JG, Nipp RD, Tramontano A, Ali A, Zhan T, Pandharipande P, Dowling EC, Ferrone CR, Hong TS, Schrag D, Fernandez-Del Castillo C, Ryan DP, Kong CY, Hur C. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. Oncologist 2019;24:945-54. [PMID: 30559125 DOI: 10.1634/theoncologist.2018-0114] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
21 Masuda H, Kotecha K, Maitra R, Gill AJ, Mittal A, Samra JS. Clinical suspicion of pancreatic cancer despite negative endoscopic ultrasound-guided fine-needle aspiration biopsy. ANZ J Surg 2021. [PMID: 34636123 DOI: 10.1111/ans.17256] [Reference Citation Analysis]
22 Kim SS, Ko AH, Nakakura EK, Wang ZJ, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Kim GE. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization? Am J Surg Pathol 2019;43:334-40. [PMID: 30211728 DOI: 10.1097/PAS.0000000000001152] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
23 Heger U, Sun H, Hinz U, Klaiber U, Tanaka M, Liu B, Sachsenmaier M, Springfeld C, Michalski CW, Büchler MW, Hackert T. Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival. HPB (Oxford) 2020;22:224-32. [PMID: 31375338 DOI: 10.1016/j.hpb.2019.06.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]